FDA restarts hepatitis D commercialization after prior rejection

Gilead won U.S. approval for its hepatitis D drug Hepcludex (bulevirtide), four years after an FDA rejection tied to manufacturing and distribution concerns. The clearance follows the company’s efforts to address the FDA’s prior requirements and restart a key commercialization pathway for chronic hepatitis D.